Dave Johnson from Caligan Partners discusses his thesis on Evolus (EOLS). Evolus is a one product company. Their product, Jeuveau, is a Botox competitor exclusively focused on the cosmetics market, and Dave thinks the market is underpricing Jeuveau's strong growth potential.

Caligan's website: https://www.caliganpartners.com/

Chapters
0:00 Intro
2:15 Caligan background
8:15 EOLS Overview
13:00 What does Dave see in EOLS that the market is missing?
19:30 Why can EOLS take share versus Botox
26:00 Why is EOLS focusing only on Cosmetics
29:30 Is M&A in EOLS's future?
33:15 EOLS acquisition targets and funding one
37:30 Getting operating leverage and hitting cash flow breakeven
40:15 What happens if we go into a recession?
43:25 What does pricing look like?
47:45 Does Daxxify's approval impact the market?
52:45 Will new entrants impact pricing for tox?
57:15 Closing thoughts